News Details

MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program

About MEI Pharma, Inc.
  • NASDAQ: $MEIP
  • Notified: $2.83
  • 17:01 EDT

Price Chart